Immunology Clinical Trials Update: Week 24, 2026

Published June 12, 2026 — 5 trials covered

By Victor Lafforgue, Founder of TrialsAlert. Blog posts are AI-drafted from ClinicalTrials.gov source data and reviewed by the editorial team. See our editorial policy for details.

Study to Evaluate the Pharmacokinetics, Efficacy, Tolerability, and Safety of Subcutaneous Human Immunoglobulin (Newnorm) in Patients With Primary Immunodeficiency Diseases

This Phase 3 trial is testing a new subcutaneous human immunoglobulin treatment named Newnorm for patients with primary immunodeficiency diseases. If the treatment proves effective and safe, it could provide a more convenient and potentially better option for managing immune deficiencies. The study currently has 50 patients enrolled across multiple countries and is active but not recruiting.

A Pilot Study Testing the Safety and Feasibility of Restorative Microbiota Therapy (RMT) in Patients With Refractory Immune-checkpoint Inhibitor-related Colitis

This Phase 2 study explores an oral therapy aimed at restoring gut microbiota in patients suffering from colitis caused by immune checkpoint inhibitors, who do not respond to steroids. This new approach might help reduce symptoms without the need for broad immune suppression. The trial is recruiting 20 patients at several U.S. locations.

COVID-19 Booster Vaccine in Autoimmune Disease Non-Responders

This Phase 2 trial investigates different COVID-19 booster vaccines for people with autoimmune diseases such as lupus, rheumatoid arthritis, and multiple sclerosis who showed poor immune responses to initial vaccines. The goal is to improve protection against COVID-19 in these vulnerable groups. The study enrolled 258 participants across 29 U.S. sites, including individuals taking immunosuppressive medications.

Omalizumab for the Treatment of Food Allergy in Patients With Elevated Total IgE Levels

This Phase 2 trial is testing omalizumab injections in people with food allergies who have high levels of IgE, a type of antibody linked to allergic reactions. If successful, this treatment could help patients better tolerate allergenic foods and expand current allergy management options. The study is recruiting 32 participants in the United States, with injections given every two weeks over 24 weeks plus an optional extension period.

LOGOGRAM: Validation of Allergy Care Flowcharts in Primary Care: Experience From Occitanie

This study is evaluating an artificial intelligence-based tool designed to assist primary care doctors in diagnosing and referring patients with allergies more accurately and quickly. The tool aims to improve patient care by reducing delays and errors in allergy management. It is recruiting 600 participants in France and focuses on common allergic conditions.

TrialsAlert subscribers received the full impact-classified briefing and doctor-ready report this week. Get weekly briefings at trialsalert.com.